The Food and Drug Administration (FDA) recently approved immune checkpoint inhibitors (ICIs) for patients with advanced or recurrent endometrial cancer (EC) who did not respond to first-line treatment with chemotherapy. This led to several new trials of emerging therapies, including studies to determine if progression-free survival (PFS) could be improved with the addition of chemotherapy. With the advent of ICI therapy and emerging ICI combination therapies, clinicians need to have knowledge of where and how maintenance therapy may play a role in improving PFS in EC. During this podcast, international gynecologic cancer experts Drs. Richard Penson and Nicoletta Colombo discuss the most recent data from these EC trials, focusing on how it has changed recommended practice patterns and how it should be incorporated into the care of patients with EC.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/planning-ahead-maintenance-therapy-in-endometrial-cancer/
- Start Date: 2024-02-01 06:00:00
- End Date: 2024-02-01 06:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine